1,900
Participants
Start Date
September 29, 2015
Primary Completion Date
September 9, 2016
Study Completion Date
November 7, 2016
MEDI7510
RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
IIV
Marketed Inactivated Influenza Vaccine
Placebo
Sterile Saline
Research Site, Pretoria
Research Site, Krugersdorp
Research Site, Johannesburg
Research Site, Johannesburg
Research Site, Somerset West
Research Site, Cape Town
Research Site, Bellville
Research Site, Bloemfontein
Research Site, Tallinn
Research Site, Tallinn
Research Site, Tallinn
Research Site, Rochester
Research Site, Winston-Salem
Research Site, Raleigh
Research Site, Rocky Mount
Research Site, Charlotte
Research Site, Hickory
Research Site, Savannah
Research Site, Lady Lake
Research Site, Orlando
Research Site, Miami
Research Site, Nashville
Research Site, Knoxville
Research Site, Akron
Research Site, Cincinnati
Research Site, Kaunas
Research Site, Council Bluffs
Research Site, Edina
Research Site, Dakota Dunes
Research Site, Chicago
Research Site, Champaign
Research Site, Kansas City
Research Site, Augusta
Research Site, Wichita
Research Site, Bellevue
Research Site, Omaha
Research Site, Norfolk
Research Site, Paide
Research Site, Aurora
Research Site, Littleton
Research Site, Murray
Research Site, San Francisco
Research Site, Sacramento
Research Site, Temuco
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Santiago
Research Site, Brampton
Research Site, London
Research Site, Newmarket
Research Site, Toronto
Research Site, Toronto
Research Site, Québec
Research Site, Daugavpils
Research Site, Jelgava
Research Site, Kuldīga
Research Site, Kaunas
Research Site, Kaunas
Research Site, Vilnius
Research Site, Vilnius
Lead Sponsor
MedImmune LLC
INDUSTRY